Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XCUR Exicure, Inc.

Pre-Mkt 11-04 07:16:54 EST

1.01

-0.01

-0.98%

盘前1.00

-0.01-0.99%

04:34 EST

High1.04	Low0.9999	Vol15.91K
Open1.01	D1 Closing1.02	Amplitude3.93%
Mkt Cap6.61M	Tradable Cap3.13M	Total Shares6.55M
T/O16.09K	T/O Rate0.51%	Tradable Shares3.10M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XCUR","market":"US","secType":"STK","nameCN":"Exicure, Inc.","latestPrice":1.01,"timestamp":1793739600000,"preClose":1.02,"halted":0,"volume":15907,"hourTrading":{"tag":"盘前","latestPrice":1,"preClose":1.01,"latestTime":"04:34 EST","volume":239,"amount":241.32970029999998,"timestamp":1793784869834,"change":-0.01,"changeRate":-0.009901,"amplitude":0.009901},"delay":0,"changeRate":-0.00980392156862746,"floatShares":3096100,"shares":6546000,"eps":-1.302239,"marketStatus":"Pre-Mkt","change":-0.01,"latestTime":"11-04 07:16:54 EST","open":1.01,"high":1.04,"low":0.9999,"amount":16086.5534439,"amplitude":0.039314,"askPrice":1.11,"askSize":100,"bidPrice":0.8688,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.302239,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1793802600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1.01,"preHourTrading":{"tag":"盘前","latestPrice":1,"preClose":1.01,"latestTime":"04:34 EST","volume":239,"amount":241.32970029999998,"timestamp":1793784869834,"change":-0.01,"changeRate":-0.009901,"amplitude":0.009901},"postHourTrading":{"tag":"盘后","latestPrice":1.01,"preClose":1.01,"latestTime":"19:30 EST","volume":52,"amount":51.9628,"timestamp":1793752204910,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.565936375849414},"requestUrl":"/m/hq/s/XCUR/tweets","defaultTab":"tweets","newsList":[{"id":"2667988218","title":"Exicure Wins NASDAQ Extension to Meet $2.5 Million Stockholders’ Equity Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2667988218","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667988218?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:04","pubTimestamp":1789560272,"startTime":"0","endTime":"0","summary":"Exicure wins Nasdaq extension to meet $2.5 million stockholders’ equity ruleExicure received a Nasdaq extension to regain compliance with Listing Rule 5550(b)(1) on minimum stockholders’ equity.The co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL5CQ3zF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","NDAQ","IE00BKPKM429.USD","BCDF","IE00BQXX3C00.GBP","BK4112","SG9999014021.USD","BK4139","LU2210150020.SGD","IE00BQXX3D17.EUR","SG9999014005.SGD","IE00BGHQF748.EUR","BK4588","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","BK4585","XCUR","LU2095319765.USD","IE00BQXX3F31.USD","SG9999014039.USD","IE00BN0W2V16.EUR","LU0314104364.USD","LU2210149790.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667881329","title":"Exicure Receives NASDAQ Extension to Regain Compliance with Stockholders’ Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2667881329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667881329?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:00","pubTimestamp":1789560004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA6VF2BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126631","title":"Exicure Q2 FY26 Net Loss Narrows 57% to $1.12 Million; Reports no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126631","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126631?lang=en_us&edition=fundamental","pubTime":"2026-08-15 03:30","pubTimestamp":1786735845,"startTime":"0","endTime":"0","summary":"Exicure Q2 FY26 net loss narrows 57% to $1.12 million; reports no revenueExicure posted a net loss of USD 1.12 million, narrowing 57% from the prior-year quarter, while revenue was flat at no revenue.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDLbHNhS4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656137459","title":"Exicure to Settle Gpcr Therapeutics Clinical Milestone Payment Through Equity Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2656137459","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656137459?lang=en_us&edition=fundamental","pubTime":"2026-08-03 21:24","pubTimestamp":1785763477,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUAJJJL9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XCUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647640556","title":"Exicure Names Jin Young Go, Eui Seok Han to Board After Ham Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2647640556","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647640556?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:40","pubTimestamp":1782823219,"startTime":"0","endTime":"0","summary":"Exicure names Jin Young Go, Eui Seok Han to board after Ham resignationExicure reshaped its board effective June 30, 2026, following the resignation of director Jung Kyu Ham.Jin Young Go joined as a C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL7pDkmD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4585","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","SG9999014013.SGD","BK4112","LU2095319765.USD","XCUR","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647563915","title":"Press Release: Exicure Announces Board and Committee Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2647563915","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647563915?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:40","pubTimestamp":1782823200,"startTime":"0","endTime":"0","summary":"WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (\"Exicure\" or the \"Company\") today announced changes to its Board of Directors and Board committees following actions a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642147565","title":"Exicure gets Nasdaq notice for falling below $2.5 million stockholders’ equity requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642147565","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642147565?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:01","pubTimestamp":1781121676,"startTime":"0","endTime":"0","summary":"Exicure received a Nasdaq notice on June 5, 2026 for failing the $2.5 million minimum stockholders’ equity requirement under Listing Rule 5550.Stockholders’ equity was about $2.1 million in its Form 10-Q for the quarter ended March 31, 2026; Nasdaq also flagged failures on alternative listing tests.The notice does not immediately affect its Nasdaq Capital Market listing.Exicure must submit a compliance plan by July 20, 2026; Nasdaq can grant up to 180 days from the notice date to regain compliance.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL7PfJgj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","BK4585","SG9999014005.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210149790.SGD","XCUR","SG9999014021.USD","LU2095319765.USD","BK4112","LU2210150020.SGD","BK4588","NDAQ","SG9999014039.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642475687","title":"Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642475687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642475687?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:01","pubTimestamp":1781121660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUA4M36KG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640626129","title":"Exicure receives noncompliance notification from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2640626129","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640626129?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:21","pubTimestamp":1780345297,"startTime":"0","endTime":"0","summary":"Exicure (XCUR) announced that it received a notification letter from Nasdaq indicating that the company was not in compliance with Nasdaq Listing R...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exicure-receives-noncompliance-notification-from-nasdaq-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exicure-receives-noncompliance-notification-from-nasdaq-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XCUR","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640961486","title":"Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q","url":"https://stock-news.laohu8.com/highlight/detail?id=2640961486","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640961486?lang=en_us&edition=fundamental","pubTime":"2026-06-02 03:31","pubTimestamp":1780342299,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nFWN4290T9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640961435","title":"Exicure - Files Q1 2026 10-Q on May 29, 2026; Believes Nasdaq Compliance Regained","url":"https://stock-news.laohu8.com/highlight/detail?id=2640961435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640961435?lang=en_us&edition=fundamental","pubTime":"2026-06-02 03:31","pubTimestamp":1780342299,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nFWN4290T9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XCUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639967099","title":"Exicure Q1 EPS $(0.29) Down From $0.49 YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2639967099","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639967099?lang=en_us&edition=fundamental","pubTime":"2026-05-30 05:36","pubTimestamp":1780090574,"startTime":"0","endTime":"0","summary":"Exicure (NASDAQ:XCUR) reported quarterly losses of $(0.29) per share. This is a 159.18 percent decrease over earnings of $0.49 per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52891233/exicure-q1-eps-0-29-down-from-0-49-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Exicure Q1 EPS $(0.29) Down From $0.49 YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TQQY","JEPQ","QQQ","QQQE","NQmain","IYW","SQQQ","ONEQ","QQQJ","QQQA","QLD","NDX","QQQM",".IXIC","NVIW.SI","FTEC","TQQQ","TECS","QQQY","QDTE","QYLG","XCUR","PSQ","GPIQ","MNQmain","QID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639671052","title":"Exicure Q1 FY26 net loss widens to $1.83 million; R&D expense drops 61% to $312,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2639671052","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639671052?lang=en_us&edition=fundamental","pubTime":"2026-05-30 02:10","pubTimestamp":1780078238,"startTime":"0","endTime":"0","summary":"Exicure posted a net loss of USD 1.83 million, swinging from net income of USD 3.01 million a year earlier.Operating results turned to an operating loss of USD 1.64 million from operating income of USD 2.92 million in the prior-year quarter.Research and development expense fell 61% to USD 312,000; general and administrative expense dropped 42% to USD 1.29 million.Cash and cash equivalents totaled about USD 2.6 million as of March 31, 2026, with management flagging substantial doubt about going-concern status.Plans include a USD 1 million milestone payment to GPCR in shares in Q2 2026 as GPCR USA advances a stem-cell mobilization study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to ge","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDLbsgqbc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037307","title":"Exicure delays filing quarterly report, seeks five-day extension under SEC rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037307","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037307?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:03","pubTimestamp":1778875391,"startTime":"0","endTime":"0","summary":"Exicure filed a Form 12b-25 to delay its quarterly report on Form 10-Q for quarter ended March 31, 2026, citing need for more time to finalize financial results and related disclosures.Filing was due May 15, 2026; company expects to submit the 10-Q within the SEC’s five-calendar-day grace period.Preliminary results show revenue of $0, net loss of about $1.83 million versus about $3.01 million a year earlier.Cash and cash equivalents expected at about $2.5 million at March 31, 2026, down from about $3.7 million at Dec. 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL61hLW2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629071752","title":"BRIEF-Exicure announces co-development agreement with Adbiotech for Burixafor (Gpc-100)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629071752","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629071752?lang=en_us&edition=fundamental","pubTime":"2026-04-23 07:57","pubTimestamp":1776902248,"startTime":"0","endTime":"0","summary":"BRIEF-Exicure announces co-development agreement with Adbiotech for Burixafor (Gpc-100)April 22 (Reuters) - Exicure Inc XCUR.O:EXICURE ANNOUNCES CO-DEVELOPMENT AGREEMENT WITH ADBIOTECH FOR BURIXAFOR (","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA70QX5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629071296","title":"Exicure partners with Adbiotech to co-develop Burixafor combination therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2629071296","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629071296?lang=en_us&edition=fundamental","pubTime":"2026-04-23 07:54","pubTimestamp":1776902079,"startTime":"0","endTime":"0","summary":"Exicure entered a co-development agreement with Korea-based Adbiotech to evaluate combination therapies using Burixafor .Collaboration targets sickle cell disease, acute myeloid leukemia, solid tumors.Adbiotech will run in vivo studies, support preclinical validation, translational research.Exicure will supply Burixafor, lead clinical and regulatory strategy.Parties may advance selected programs into IND-enabling studies, clinical trials, subject to a subsequent definitive agreement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL6ZqPK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014013.SGD","IE00BGHQF748.EUR","BK4139","BK4112","LU2210150020.SGD","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4588","LU0314104364.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014039.USD","XCUR","LU2095319765.USD","IE00BN0W2V16.EUR","SG9999014021.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629071250","title":"Exicure Announces Co-Development Agreement With Adbiotech for Burixafor (Gpc-100)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629071250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629071250?lang=en_us&edition=fundamental","pubTime":"2026-04-23 07:54","pubTimestamp":1776902061,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA70QX5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626214885","title":"Exicure names Young Seung Ko chief operating officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626214885","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626214885?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:17","pubTimestamp":1775852251,"startTime":"0","endTime":"0","summary":"Exicure appointed Young Seung Ko as chief operating officer effective April 9, 2026.Ko previously served as CEO and director of AGEDB Technology Ltd. from September 2022 to March 2025.He also held role as director of global operations at Bitnine Global from October 2020 to September 2024.Audit committee leadership shifted, with Dongho Lee appointed chair.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL5Yv5TJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624568408","title":"Exicure Inc - Announces Settlement of Stockholder Derivative Action per March 18, 2026 Stipulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2624568408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624568408?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:03","pubTimestamp":1775160222,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L10Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XCUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624747684","title":"Exicure reaches settlement in stockholder derivative litigation, adopts governance reforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2624747684","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624747684?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:01","pubTimestamp":1775160109,"startTime":"0","endTime":"0","summary":"Exicure reached settlement in consolidated stockholder derivative litigation in US District Court for Northern District of Illinois.Agreement requires corporate governance reforms to be implemented, maintained for four years.Claims alleged board-level failures in internal controls tied to study data collection, analysis, reporting, public disclosures, causing reputational, financial harm.Settlement includes USD 0.7 million in plaintiffs’ attorneys’ fees, paid by insurers, subject to court approval.Settlement hearing is set for June 2, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL8Ngvh4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","LU2210150020.SGD","NDAQ","BK4588","LU2095319765.USD","XCUR","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","IE00B64PRP62.GBP","SG9999014005.SGD","SG9999014021.USD","IE00BKPKM429.USD","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.exicuretx.com","stockEarnings":[{"period":"1week","weight":-0.0561},{"period":"1month","weight":-0.1217},{"period":"3month","weight":-0.3311},{"period":"6month","weight":-0.6985},{"period":"1year","weight":-0.7601},{"period":"ytd","weight":-0.8137}],"compareEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.0199},{"period":"3month","weight":-0.0201},{"period":"6month","weight":0.0311},{"period":"1year","weight":0.1039},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Exicure, Inc. does not have significant operations. previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.050352},{"month":2,"riseRate":0.375,"avgChangeRate":-0.040535},{"month":3,"riseRate":0.375,"avgChangeRate":-0.031749},{"month":4,"riseRate":0.375,"avgChangeRate":-0.028338},{"month":5,"riseRate":0.25,"avgChangeRate":-0.028013},{"month":6,"riseRate":0.222222,"avgChangeRate":-0.076219},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.072426},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.07587},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.037233},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.074341},{"month":11,"riseRate":0.444444,"avgChangeRate":0.887077},{"month":12,"riseRate":0.5,"avgChangeRate":-0.072048}],"exchange":"NASDAQ","name":"Exicure, Inc.","nameEN":"Exicure, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Exicure, Inc.(XCUR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Exicure, Inc.,XCUR,Exicure, Inc.股票,Exicure, Inc.股票老虎,Exicure, Inc.股票老虎国际,Exicure, Inc.行情,Exicure, Inc.股票行情,Exicure, Inc.股价,Exicure, Inc.股市,Exicure, Inc.股票价格,Exicure, Inc.股票交易,Exicure, Inc.股票购买,Exicure, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Exicure, Inc.(XCUR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction